Johnson & Johnson announces Phase 2b data from JNJ-4804 studies

Johnson & Johnson announced Phase 2b data from two studies evaluating JNJ-4804, an investigational co-antibody therapy targeting both interleukin-23 and tumor necrosis factor-alpha , in patients with moderately to severely active ulcerative colitis or Crohn’s disease that is refractory to systemic therapies. The late-breaking presentations from the DUET-UC and DUET-CD studies were among the 32 company-sponsored abstracts being presented at Digestive Disease Week 2026. In both studies at Week 48, JNJ-4804 showed meaningful improvements across multiple clinical and endoscopic measures for a subpopulation of patients who are considered highly refractory and have had inadequate response to two or more systemic therapy classes.